LY 354740

Pricing Availability   Qty
Description: Potent and highly selective group II mGlu agonist
Chemical Name: (1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
Purity: ≥98% (HPLC)
Datasheet
Citations (5)
Reviews
Literature (4)

Biological Activity for LY 354740

LY 354740 is a highly selective and potent agonist of group II mGlu receptors (EC50 values are 5.1 and 24.3 nM at mGlu2 and mGlu3 receptors respectively and > 100000 nM at mGlu4, mGlu7, mGlu1a and mGlu5a receptors). Displays antianxiety and antiaddictive activity in vivo. Orally and systemically active.

Technical Data for LY 354740

M. Wt 185.18
Formula C8H11NO4
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 176199-48-7
PubChem ID 213056
InChI Key VTAARTQTOOYTES-RGDLXGNYSA-N
Smiles N[C@]1([C@@](O)=O)[C@@]2([H])[C@@]([C@@H]2[C@](O)=O)([H])CC1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for LY 354740

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
1eq. NaOH 18.52 100

Preparing Stock Solutions for LY 354740

The following data is based on the product molecular weight 185.18. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 5.4 mL 27 mL 54 mL
5 mM 1.08 mL 5.4 mL 10.8 mL
10 mM 0.54 mL 2.7 mL 5.4 mL
50 mM 0.11 mL 0.54 mL 1.08 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for LY 354740

Certificate of Analysis / Product Datasheet
Select another batch:

References for LY 354740

References are publications that support the biological activity of the product.

Schoepp et al (1997) LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cell expressing human glutamate receptors. Neuropharmacology 36 1 PMID: 9144636

Helton et al (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J.Pharmacol.Exp.Ther. 284 651 PMID: 9454811

Klodzinska et al (1999) Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38 1831 PMID: 10608278


If you know of a relevant reference for LY 354740, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group II Receptor Agonists

Keywords: LY 354740, LY 354740 supplier, Potent, selective, group, II, mGlur, agonists, Group, Receptors, mGlu2, mGluR2, mGlu3, mGluR3, Glutamate, Metabotropic, LY354740, (Metabotropic), 3246, Tocris Bioscience

5 Citations for LY 354740

Citations are publications that use Tocris products. Selected citations for LY 354740 include:

Yaeger and Trussell (2015) Single granule cells excite Golgi cells and evoke feedback inhibition in the cochlear nucleus. J Neurosci 35 4741 PMID: 25788690

Copeland et al (2015) Neuronal activity patterns in the mediodorsal thalamus and related cognitive circuits are modulated by metabotropic glutamate receptors. Sci Rep 92 16 PMID: 25576798

Chai et al (2017) Neural Circuit-Specialized Astrocytes: Transcriptomic, Proteomic, Morphological, and Functional Evidence. Neuron 95 531 PMID: 28712653

Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236


Do you know of a great paper that uses LY 354740 from Tocris? Please let us know.

Reviews for LY 354740

There are currently no reviews for this product. Be the first to review LY 354740 and earn rewards!

Have you used LY 354740?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.